Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)
China · Delayed Price · Currency is CNY 35.72
+0.17 (0.48%)
Sep 1, 2026, 4:00 PM EDT
SHA:688163 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,866 | 2,356 | 1,900 | 2,163 | 2,282 | - | |
Market Cap Growth | 45.14% | 23.97% | -12.16% | -5.22% | - | - |
Enterprise Value | 3,128 | 1,574 | 1,053 | 1,312 | 1,366 | - |
Last Close Price | 35.72 | 21.62 | 17.17 | 19.10 | 19.53 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 70.14 | 45.49 | 42.91 | 55.79 | 35.55 | - |
PS Ratio | 19.37 | 12.01 | 9.75 | 11.38 | 13.10 | - |
PB Ratio | 3.45 | 2.12 | 1.74 | 1.99 | 2.04 | - |
P/TBV Ratio | 3.52 | 2.16 | 1.77 | 2.04 | 2.08 | - |
P/FCF Ratio | 167.61 | 2545.69 | - | 521.89 | 55.06 | - |
P/OCF Ratio | 43.04 | 38.92 | 37.82 | 65.92 | 33.61 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 15.67 | 8.02 | 5.40 | 6.90 | 7.84 | - |
EV/EBITDA Ratio | 38.56 | 22.21 | 16.04 | 26.52 | 21.21 | - |
EV/EBIT Ratio | 52.48 | 30.12 | 22.82 | 39.49 | 27.09 | - |
EV/FCF Ratio | 135.63 | 1700.40 | - | 316.44 | 32.96 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.04 |
Debt / EBITDA Ratio | 0.06 | 0.07 | 0.06 | 0.26 | 0.21 | 0.15 |
Debt / FCF Ratio | 0.21 | 5.51 | - | 3.13 | 0.33 | 0.22 |
Net Debt / Equity Ratio | -0.66 | -0.72 | -0.76 | -0.79 | -0.82 | -0.45 |
Net Debt / EBITDA Ratio | -9.19 | -11.34 | -12.62 | -17.40 | -14.27 | -1.73 |
Net Debt / FCF Ratio | -31.98 | -868.46 | 90.87 | -207.60 | -22.18 | -2.58 |
Asset Turnover | 0.17 | 0.17 | 0.17 | 0.17 | 0.22 | 0.58 |
Inventory Turnover | 1.06 | 1.04 | 1.04 | 1.00 | 0.65 | 0.74 |
Quick Ratio | 14.92 | 23.19 | 44.34 | 35.90 | 35.06 | 11.16 |
Current Ratio | 16.08 | 24.72 | 46.70 | 37.98 | 37.10 | 14.05 |
Return on Equity (ROE) | 4.89% | 4.69% | 4.06% | 3.51% | 8.61% | 23.03% |
Return on Assets (ROA) | 3.21% | 2.87% | 2.56% | 1.81% | 4.02% | 14.34% |
Return on Invested Capital (ROIC) | 13.29% | 14.63% | 16.41% | 13.28% | 21.61% | 37.64% |
Return on Capital Employed (ROCE) | 5.30% | 4.70% | 4.20% | 3.00% | 4.40% | 21.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.41% | 2.20% | 2.33% | 1.79% | 2.81% | - |
FCF Yield | 0.60% | 0.04% | -0.48% | 0.19% | 1.82% | - |
Dividend Yield | 1.15% | 1.76% | 1.86% | 1.05% | 3.84% | - |
Payout Ratio | 75.50% | 66.86% | 78.18% | 209.31% | 151.70% | - |
Buyback Yield / Dilution | 2.01% | 0.13% | -0.30% | -5.70% | -25.24% | -0.46% |
Total Shareholder Return | 3.16% | 1.88% | 1.57% | -4.65% | -21.40% | -0.46% |